CAP TODAY/Thermo Fisher Scientific/Spectrum Pharmaceuticals Webinar: Enabling precision oncology care through collaboration: testing before treating ERBB2/HER2 mutations in mNSCLC

Thank you

This live web event has ended. Thank you for attending.

Description

Enabling precision oncology care through collaboration: testing before treating ERBB2/HER2 mutations in mNSCLC

Why should you register now for this webinar?
Hear national thought leaders discuss the rapidly evolving biomarker landscape in metastatic non-small cell lung cancer (NSCLC), with the focus on emerging ERBB2/HER2 mutations, including exon 20 insertions. The oncologist and pathologist speakers will discuss their roles within the context of a multidisciplinary team to enable precision oncology care.
Brought to you by: CAP TODAY
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Presenters: Narjust Florez, MD, and Salvatore Priore, MD, PhD

What will this webinar empower you to do?

Deepen your understanding of the role of biomarkers testing in lung cancer care
Review clinically relevant biomarkers, including emerging ERBB2/HER2 mutations
Hear considerations for a collaborative approach to enabling precision oncology
Ask questions of our distinguished presenters

CAP TODAY does not endorse any of the products or services named within.
The webinar is made possible by a special educational grant from Thermo Fisher Scientific.

Contributors

Narjust Florez, MD

Dana-Farber Cancer Institute
Salvatore Priore, MD, PhD

Assistant Professor of Clinical Pathology and
Laboratory Medicine, Perelman School of Medicine
at the University of Pennsylvania; Associate Director,
Molecular Genetic Pathology Fellowship
Bob McGonnagle

Publisher, CAP TODAY